Organization
Curie Institute
6 abstracts
Abstract
Dynamics and type of ESR1 mutations under aromatase inhibitor or fulvestrant combined with palbociclib after randomization in the PADA-1 trial.Org: Gustave Roussy Cancer Center, CARIO - HPCA, Department of Genetics, Claudius Regaud Institute, Eugène Marquis Comprehensive Cancer Center,
Abstract
First-line systemic treatment with palbociclib in women aged ≥70 years presenting with hormone receptor-positive advanced breast cancer: Results from the PALOMAGE program.Org: PACAN platform, Unité d'Oncogériatrie, Department of Geriatrics, Institut Paoli-Calmettes, Marseille, France, Institut Curie, Saint Cloud, France,
Abstract
Early prediction of endocrine responsiveness in ER+/HER2 negative MBC: Pilot study with 18F-fluoroestradiol (18F-FES) CT/PET.Org: EO Ospedali Galliera, University Hospital Munich, International Breast Cancer Center (IBCC), Vall d'Hebron Institute of Oncology, Maggiore della Carità University Hospital,
Abstract
Phase II basket trial evaluating the efficacy of pembrolizumab (PE) combined with vorinostat (VO) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma (SCC).Org: Curie Institute, Institut de Cancerologie de l'Ouest, Saint-Herblain, France, ICO Institut de Cancerologie de l'Ouest, Drug Development and Innovation Department, Center Georges-Francois Leclerc,
Abstract
PLUME: A single-arm phase II trial evaluating the combination of pembrolizumab and lenvatinib in metastatic uveal melanoma (mUM) patients (pts) previously treated or not with tebentafusp.Org: Institut Curie, Saint Cloud, France, Curie Institute, Department of Drug Development and Innovation (D3i),
Abstract
Tebentafusp (tebe) in a real-world cohort of 72 French metastatic uveal melanoma (UM) patients (pts).Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Institut Curie, Saint Cloud, France, APHP-INSERM U1149 Universite Paris Diderot, Curie Institute, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,